Holen Sie sich die Stockscreener-App
1.36
0.37%
0.01
Schlusskurs vom Vortag:
$1.35
Offen:
$1.38
24-Stunden-Volumen:
206.78K
Relative Volume:
0.13
Marktkapitalisierung:
$46.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.14M
KGV:
-2.5185
EPS:
-0.54
Netto-Cashflow:
$-3.99M
1W Leistung:
-8.45%
1M Leistung:
-5.24%
6M Leistung:
-23.01%
1J Leistung:
-70.99%
1-Tages-Spanne:
$1.35
$1.42
1-Wochen-Bereich:
$1.34
$1.486
52-Wochen-Spanne:
$1.12
$5.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Firmenname
Telomir Pharmaceuticals Inc
Sektor
Branche
Telefon
786-396-6723
Adresse
100 SE 2ND ST, MIAMI
Vergleichen Sie TELO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.355 | 46.41M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.51 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.61 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
849.65 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.24 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
165.06 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-21 | Eingeleitet | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 PostEarnings & Community Driven Trade Alerts - Улправда
Can Telomir Pharmaceuticals Inc. stock sustain revenue growth2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - ACCESS Newswire
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Action & Accurate Buy Signal Alerts - Улправда
Telomir Pharmaceuticals Reports Positive IND-Enabling Study Results - TipRanks
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death - MSN
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - USA Today
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - Daily Commercial
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Telomir Pharmaceuticals Inc. stock attracts high net worth investorsTrade Signal Summary & Free Community Supported Trade Ideas - Newser
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 2.3% – Still a Buy? - Defense World
Telomir Pharmaceuticals announces new preclinical data on Telomir-1 - MSN
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support - marketscreener.com
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data - MSN
Telomir reports PSA reduction in prostate cancer cells with lead drug - Investing.com Nigeria
Telomir reports PSA reduction in prostate cancer cells with lead drug By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Reports Promising Preclinical Data - TipRanks
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event | TELO SEC FilingForm 8-K - Stock Titan
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Bluffton Today
Will Telomir Pharmaceuticals Bounce Back? - StocksToTrade
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025 - ts2.tech
Telomir stock surges after leukemia cell-killing data By Investing.com - Investing.com Nigeria
Telomir stock surges after leukemia cell-killing data - Investing.com UK
Telomir Pharma (NASDAQ: TELO) Telomir-1 Shows Preclinical HL60 Leukemia Activity - Stock Titan
Telomir Pharmaceuticals director Craig Eagle resigns from board By Investing.com - Investing.com Australia
Telomir Pharmaceuticals director Craig Eagle resigns from board - Investing.com
Telomir Pharmaceuticals Inc. Announces Resignation of Craig Eagle as Director, Effective on November 14, 2025 - MarketScreener
Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy - TipRanks
Telomir Pharmaceuticals, Inc. Announces Telomir-1 Kills Aggressive Human Leukemia Cells - marketscreener.com
How Telomir Pharmaceuticals Inc. stock performs after earnings2025 Market Overview & Precise Buy Zone Tips - newser.com
Does Telomir Pharmaceuticals Inc. stock trade at a discount to peersQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Will Telomir Pharmaceuticals Inc. bounce back from current supportMarket Activity Recap & Precise Buy Zone Tips - newser.com
Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):